# Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it

Source: https://onco.cc/roadmaps/rejuvenation-roadmap/  
OnCo record `rejuvenation-roadmap` (Roadmap). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Recovery became a research subject because children started surviving cancer and someone wrote down what the cure had cost. Sixty years later the damage is well measured, exercise is the only thing proven to change a hard outcome, and the next decade turns on whether anyone funds the trials and the services the evidence already justifies.

## Summary

Five things had to happen before this field could exist. Cancer had to become curable, which happened in paediatric oncology first. Someone had to say that cure was not the end of the question, which Giulio D'Angio did in 1975 and Fitzhugh Mullan did for adults in 1985. The people it was happening to had to organise, which they did in Albuquerque in 1986 and which produced the definition of survivor that national institutes now use. The cost had to be measured in cohorts large enough to attribute a late effect to a dose, which the Childhood Cancer Survivor Study and its successors did from 1994. And a report had to define what good survivorship care consists of, which the Institute of Medicine did in 2006.

What followed is a more mixed record than that sequence suggests. The instrument the 2006 report invented, the survivorship care plan, was mandated into accreditation standards and then failed its randomised trials; the 2018 systematic review's verdict is that existing research provides little evidence that such plans improve health outcomes and health care delivery. The national programme England ran from 2007 produced a sensible minimum bundle and measured that only a quarter of people were offered the least demanding part of it. Meanwhile de-escalation worked: late mortality after childhood cancer fell because treatment was made gentler on the strength of cohort evidence, which is the field's clearest success and is a success in prevention rather than in repair.

The decisive result arrived in 2025. The CHALLENGE trial randomised 889 people with resected colon cancer after adjuvant chemotherapy to a three-year coached exercise programme or to health-education materials, and found longer disease-free survival (hazard ratio 0.72) and longer overall survival (hazard ratio for death 0.63), with eight-year overall survival of 90.3 against 83.2 per cent. That is the first randomised proof that something done after treatment changes whether the cancer comes back, and it is the benchmark every rejuvenation claim should now be measured against.

The frontier runs in the opposite direction. Cancer treatment measurably accelerates epigenetic clocks, senescence markers and physiological frailty; nothing has been shown to reverse any of it; and a retail industry selling stem cell infusions, exosomes, unlicensed peptides, intravenous NAD+ and compounded hormone pellets to people who have just finished treatment has grown up in the gap between the measurement and the evidence. The honest statement of the field's position is that the acceleration is real, nothing sold on the strength of it has been shown to reverse it, and the distance between those two sentences is where the research belongs.

What the next decade turns on is unusually clear and unusually unglamorous: endpoints the field has not agreed, registries that do not record late effects, services that are recommended and not commissioned, and follow-up nobody owns. None of it needs a discovery.

## Fields

- Kind: Roadmap
- Last checked: 2026-10-02
- Also known as: Survivorship research roadmap; Recovery roadmap; Rejuvenation roadmap; History of survivorship research

## Sources

- Mullan, Seasons of survival: reflections of a physician with cancer (New England Journal of Medicine 1985;313:270-273): https://doi.org/10.1056/NEJM198507253130421
- Institute of Medicine and National Research Council, From Cancer Patient to Cancer Survivor: Lost in Transition (National Academies Press 2006): https://doi.org/10.17226/11468
- Courneya et al., Structured exercise after adjuvant chemotherapy for colon cancer, the CHALLENGE trial (NEJM 2025;393:13-25): https://doi.org/10.1056/NEJMoa2502760
- NCI Office of Cancer Survivorship: statistics and graphs: https://cancercontrol.cancer.gov/ocs/statistics
- Department of Health, Living With and Beyond Cancer: Taking Action to Improve Outcomes (England, 29 March 2013): https://www.gov.uk/government/publications/living-with-and-beyond-cancer-taking-action-to-improve-outcomes

## Connected records

- roadmaps: [Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment](https://onco.cc/roadmaps/nutrition-lifestyle-roadmap/), [Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first](https://onco.cc/roadmaps/paediatric-oncology-roadmap/), [Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards](https://onco.cc/roadmaps/survivorship-roadmap/)
- ideas: [Agree what to measure, so the next systematic review can pool rather than narrate](https://onco.cc/ideas/idea-rejuv-core-outcome-set-for-late-effects/), [Ask whether survivorship screening saves lives, using registry-based randomisation](https://onco.cc/ideas/idea-rejuv-registry-randomised-screening-in-survivors/), [Enrol every new systemic therapy into a registry linkage that will still report in thirty years](https://onco.cc/ideas/idea-rejuv-second-cancer-latency-cohort-for-new-drugs/), [Find out whether an adult thymus can be made to work again, with an endpoint a clinician would act on](https://onco.cc/ideas/idea-rejuv-thymic-regeneration-in-adults/), [Give survivorship interventions a shared control arm](https://onco.cc/ideas/idea-rejuv-survivorship-platform-trial/), [Make the treatment exposure record machine-readable, so surveillance can be computed](https://onco.cc/ideas/idea-rejuv-exposure-record-a-machine-can-read/), [Put a biological-age marker in a trial that also measures something a person would notice](https://onco.cc/ideas/idea-rejuv-biological-age-as-a-randomised-endpoint/), [Risk-stratified follow-up: low-risk survivors to primary care with fast re-entry](https://onco.cc/ideas/idea-acc-risk-stratified-follow-up/), [Survivorship care plans generated automatically from the treatment record](https://onco.cc/ideas/idea-acc-auto-generated-survivorship-plans/), [Write a rehabilitation prescription at the end of treatment, and fund it like a drug](https://onco.cc/ideas/idea-rejuv-rehabilitation-prescription-at-discharge/)
- collections: [British Childhood Cancer Survivor Study (BCCSS)](https://onco.cc/collections/bccss/), [International Guideline Harmonization Group for late effects of childhood cancer](https://onco.cc/collections/ighg/), [PanCareSurFup and the European survivor cohorts](https://onco.cc/collections/pancaresurfup/), [St Jude Lifetime Cohort Study (SJLIFE)](https://onco.cc/collections/sjlife/)
- fronts: [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [Cardio-oncology](https://onco.cc/technologies/cardio-oncology/), [Cognitive behavioural therapy for insomnia (CBT-I)](https://onco.cc/technologies/cbt-insomnia-cancer/), [Dry mouth, teeth and taste after head and neck radiotherapy](https://onco.cc/technologies/dry-mouth-teeth-after-head-neck-radiotherapy/), [Epigenetic age after cancer treatment](https://onco.cc/technologies/rejuv-age-epigenetic-clocks/), [Exercise & lifestyle oncology](https://onco.cc/technologies/exercise-oncology/), [Exosome injections](https://onco.cc/technologies/rejuv-frontier-exosome-injections/), [Fatigue after cancer treatment: what actually works](https://onco.cc/technologies/cancer-related-fatigue-management/), [Fear that the cancer will come back: how common it is, and when it stops being ordinary worry](https://onco.cc/technologies/rejuv-mind-fear-of-recurrence/), [Frailty and late effects in survivors](https://onco.cc/technologies/rejuv-age-frailty-and-late-effects/), [Going back to work after cancer: the rates, and the programmes that change them](https://onco.cc/technologies/rejuv-life-return-to-work/), [How much illness childhood cancer survivors carry, and at what age](https://onco.cc/technologies/rejuv-paed-chronic-disease-burden/), [Intravenous NAD+ drips](https://onco.cc/technologies/rejuv-frontier-nad-infusions/), [Late deaths after childhood cancer, what causes them, and the proof that gentler treatment worked](https://onco.cc/technologies/rejuv-paed-late-mortality/), [Late effects after a stem cell transplant](https://onco.cc/technologies/rejuv-tx-late-effects-overview/), [Mesenchymal stromal cells for tissue damage](https://onco.cc/technologies/rejuv-frontier-mesenchymal-stromal-cells/), [Oncofertility and fertility preservation](https://onco.cc/technologies/fertility-preservation/), [Prehabilitation before cancer surgery](https://onco.cc/technologies/prehabilitation/), [Scalp cooling (cold caps: DigniCap, Paxman)](https://onco.cc/technologies/scalp-cooling/), [Second cancers after childhood cancer: the risk by treatment, and why it is falling](https://onco.cc/technologies/rejuv-paed-second-cancers/), [Senescent cells and p16 after chemotherapy](https://onco.cc/technologies/rejuv-age-senescent-cells-after-treatment/), [Senolytics after cancer treatment](https://onco.cc/technologies/rejuv-frontier-senolytics/), [Skin during and after radiotherapy: dressings, steroids and what lasts](https://onco.cc/technologies/radiation-skin-recovery/), [Stem cell clinics and stem cell tourism](https://onco.cc/technologies/rejuv-frontier-stem-cell-tourism/), [Structured exercise programmes after curative treatment](https://onco.cc/technologies/structured-exercise-survivorship/), [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/), [Telomere length after treatment](https://onco.cc/technologies/rejuv-age-telomere-length/), [The Children's Oncology Group Long-Term Follow-Up Guidelines](https://onco.cc/technologies/rejuv-paed-cog-ltfu-guidelines/), [The exercise prescription after cancer: the dose the guidelines state](https://onco.cc/technologies/exercise-prescription-after-cancer/), [The word survivor, and why the vocabulary is not a detail](https://onco.cc/technologies/rejuv-mind-the-word-survivor/), [What actually works after treatment](https://onco.cc/technologies/rejuv-frontier-what-works/)
- terms: [Counting the people who live after cancer, and why the number is not a detail](https://onco.cc/terms/rejuv-history-counting-survivors/), [Cure is not enough: when late effects stopped being an afterthought](https://onco.cc/terms/rejuv-history-cure-is-not-enough/), [Lost in Transition: the 2006 report that defined survivorship care, and the care plan it invented](https://onco.cc/terms/rejuv-history-lost-in-transition/), [Screening survivors: where the UK, American and European answers differ](https://onco.cc/terms/rejuv-second-screening-after-treatment-compared/), [Seasons of Survival: the 1985 essay that named the problem](https://onco.cc/terms/rejuv-history-seasons-of-survival/), [Second cancers after treatment: what the risk is, and what is done about it](https://onco.cc/terms/rejuv-second-cancers-overview/), [The founding of the National Coalition for Cancer Survivorship, and the word survivor](https://onco.cc/terms/rejuv-history-survivorship-movement/), [The National Cancer Survivorship Initiative in England, and the Recovery Package](https://onco.cc/terms/rejuv-history-ncsi-england/)
- trials: [AlloCare: a stepped-care late-effects service after allogeneic transplant](https://onco.cc/trials/rejuv-trial-allocare/), [AMICO: aerobic or resistance exercise to improve outcome in metastatic colorectal cancer](https://onco.cc/trials/rejuv-trial-amico/), [CanWork: an occupational therapy programme to help women return to work after breast cancer](https://onco.cc/trials/rejuv-trial-canwork/), [CHALLENGE (CCTG CO.21)](https://onco.cc/trials/challenge/), [Childhood Cancer Survivor Study (CCSS)](https://onco.cc/trials/ccss/), [EX-CIPN: virtual exercise-based rehabilitation for persistent chemotherapy nerve damage](https://onco.cc/trials/rejuv-trial-ex-cipn/), [PROFFi: fisetin and exercise to prevent frailty in breast cancer survivors](https://onco.cc/trials/rejuv-trial-proffi/)
- people: [Ellen L. Stovall](https://onco.cc/people/ellen-stovall/), [Fitzhugh Mullan](https://onco.cc/people/fitzhugh-mullan/), [Kerry S. Courneya](https://onco.cc/people/kerry-courneya/)
- bottlenecks: [Funding follows fashion, not burden](https://onco.cc/bottlenecks/b-funding-allocation/), [No randomised trial shows that any survivorship screening programme reduces death](https://onco.cc/bottlenecks/rejuv-agenda-screening-without-a-trial/), [No treatment restores the thinking that cancer treatment takes](https://onco.cc/bottlenecks/rejuv-agenda-nothing-restores-cognition/), [Nobody has tested whether reversing measured biological ageing changes anything](https://onco.cc/bottlenecks/rejuv-agenda-biological-age-as-an-untested-target/), [Nobody owns the follow-up once the oncology clinic lets go](https://onco.cc/bottlenecks/rejuv-agenda-nobody-owns-the-follow-up/), [Nothing in routine use rebuilds an adult's thymus](https://onco.cc/bottlenecks/rejuv-agenda-thymus-does-not-regrow/), [Registries count diagnoses and deaths, and not what treatment left behind](https://onco.cc/bottlenecks/rejuv-agenda-late-effects-are-not-counted/), [Rehabilitation is recommended everywhere and commissioned almost nowhere](https://onco.cc/bottlenecks/rejuv-agenda-rehabilitation-not-commissioned/), [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/), [The field cannot pool its own studies, because it has not agreed what to measure](https://onco.cc/bottlenecks/rejuv-agenda-no-agreed-outcome-measures/), [The newest treatments have not existed long enough for their late effects to appear](https://onco.cc/bottlenecks/rejuv-agenda-latency-outruns-the-evidence/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)
- journals: [Journal of cancer survivorship](https://onco.cc/journals/journal-of-cancer-survivorship/)

---
JSON: https://onco.cc/api/v1/entities/rejuvenation-roadmap.json